Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

EBRD Invests €22 Million to Propel Farmak’s Expansion into Polish Market

(IN BRIEF) The European Bank for Reconstruction and Development (EBRD) has provided a €22 million loan to Ukrainian pharmaceutical giant Farmak Group to facilitate its strategic acquisition of a Polish pharmaceutical company and to upgrade its IT systems. Farmak, a … Read the full press release

WACKER and Pantherna Collaborate to Ramp Up mRNA Production for ARDS Treatment

(IN BRIEF) WACKER’s mRNA competence center in Halle is gearing up to produce an active ingredient for combatting acute respiratory distress syndrome (ARDS) in collaboration with Pantherna Therapeutics. The center, equipped with four new production lines, will more than triple … Read the full press release

AstraZeneca’s Imfinzi Shows Promising Results in Phase III Trial for Small Cell Lung Cancer

(IN BRIEF) AstraZeneca announces positive outcomes from the ADRIATIC Phase III trial, revealing that its immunotherapy drug Imfinzi (durvalumab) demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) among patients with limited-stage small cell lung cancer (LS-SCLC) … Read the full press release

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release

AstraZeneca and Daiichi Sankyo’s BLA for Datopotamab Deruxtecan Accepted by FDA for Advanced Breast Cancer Treatment

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US FDA for treating adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior systemic … Read the full press release

AstraZeneca and Sanofi’s Beyfortus Receives Approval in Japan for Prophylaxis against Respiratory Syncytial Virus

(IN BRIEF) AstraZeneca and Sanofi celebrate the approval of Beyfortus (nirsevimab) in Japan by the Ministry of Health, Labour, and Welfare for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in neonates, infants, and children entering … Read the full press release

AstraZeneca’s Truqap Gets Green Light in Japan for Advanced Breast Cancer Treatment

(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release

Merck Expands M LabTM Collaboration Center in Shanghai, Enhancing Biopharmaceutical Capabilities

(IN BRIEF) Merck, a prominent science and technology company, announces a €14 million expansion of its M LabTM Collaboration Center in Shanghai, bolstering its support for the biopharmaceutical industry in China. The expansion includes new facilities such as a biology … Read the full press release

Mubadala Acquires KELIX bio, Expanding Access to Life-Saving Pharmaceuticals in Emerging Markets

(IN BRIEF) DPI, BII, and the EBRD have reached a binding agreement to fully exit their investment in KELIX bio, a pan-African biopharmaceutical platform, through its acquisition by Mubadala Investment Company. Founded in 2020, KELIX bio has rapidly grown to … Read the full press release

Novo Nordisk Acquires Cardior Pharmaceuticals in Billion-Euro Deal, Pioneering RNA Therapies for Heart Diseases

(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release

Ultomiris Receives FDA Approval as First Long-Acting Treatment for AQP4 Ab+ NMOSD, Redefining Patient Care

(IN BRIEF) Ultomiris (ravulizumab-cwvz) has gained approval from the FDA as the inaugural long-acting C5 complement inhibitor for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval, based on the CHAMPION-NMOSD Phase III trial’s … Read the full press release

Novartis’ Fabhalta Receives Positive CHMP Opinion for PNH Treatment: A Potential Game-Changer

(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release

Evotec-Backed Breakpoint Therapeutics Nominates Breakthrough Cancer Treatment Candidate BTX-011 for Clinical Development

(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release

Evonik Receives Second Consecutive Asia-Pacific Bioprocessing Excellence Award for Cell Culture Solutions

(IN BRIEF) Evonik has been honored with the Asia-Pacific Bioprocessing Excellence Award (ABEA) for the second consecutive year, specifically in the category of Best New Bioprocessing Supplier Award: Upstream Processing, for its Cell Culture Solutions portfolio. As a crucial component … Read the full press release

EQT Life Sciences Portfolio Company Amolyt Pharma Acquired by Alexion, AstraZeneca Rare Diseases for $1.05 Billion

(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release

Evonik Vland Biotech Launches Joint Venture to Enhance Animal Gut Health Solutions

(IN BRIEF) The joint venture, Evonik Vland Biotech, established by Evonik China and Shandong Vland Biotech, officially commenced operations in Binzhou, China, aiming to bolster the market presence of probiotics for livestock gut health in the Greater China region while … Read the full press release

Evonik’s EUDRAGIT® Polymers: Pioneering Pharmaceutical Innovation for 70 Years

(IN BRIEF) Evonik’s EUDRAGIT® polymers, renowned coatings for pharmaceuticals, celebrate 70 years of revolutionizing drug delivery. With over 23,000 patents and 10,000 scientific publications, these methacrylate polymers have become industry standards, employed in formulations for modified drug release across 80 … Read the full press release

Tubulis Secures €128 Million Series B2 Financing to Advance Novel ADC Pipeline for Cancer Treatment

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release

Health Canada Authorizes Probiotic Strain CLEPIUS™ for Alleviating Digestive Discomfort and Stress

(IN BRIEF) Health Canada has approved functional claims for Novonesis’ probiotic strain CLEPIUS™, acknowledging its efficacy in alleviating symptoms of irritable bowel syndrome (IBS) and improving quality of life in adults. The authorization encompasses a range of benefits, including relief … Read the full press release

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release